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Abstract: Randomized controlled trials (RCTs) are the hallmark of evidence-based medicine 
and form the basis for translating research data into clinical practice. This review summarizes 
commonly applied designs and quality indicators of RCTs to provide guidance in interpreting 
and critically evaluating clinical research data. It further reflects on the principle of equipoise and 
its practical applicability to clinical science with an emphasis on critical care and neurological 
research. We performed a review of educational material, review articles, methodological studies, 
and published clinical trials using the databases MEDLINE, PubMed, and ClinicalTrials.gov. 
The most relevant recommendations regarding design, conduction, and reporting of RCTs 
may include the following: 1) clinically relevant end points should be defined a priori, and an 
unbiased analysis and report of the study results should be warranted, 2) both significant and 
nonsignificant results should be objectively reported and published, 3) structured study design 
and performance as indicated in the Consolidated Standards of Reporting Trials statement 
should be employed as well as registration in a public trial database, 4) potential conflicts of 
interest and funding sources should be disclaimed in study report or publication, and 5) in the 
comparison of experimental treatment with standard care, preplanned interim analyses during 
an ongoing RCT can aid in maintaining clinical equipoise by assessing benefit, harm, or futility, 
thus allowing decision on continuation or termination of the trial.
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Introduction
With respect to study design, randomized controlled trials (RCTs) as well as analysis 
of quantitatively synthesized RCT data are considered the gold standard for evaluating 
efficacy in clinical research and constitute evidence for medical treatment. Thus, RCT 
data are guiding physicians toward evidence-based therapy. However, interpretability 
of RCT data can be jeopardized by systematic error (bias), random error, or limited 
generalizability; problems that are usually rooted in shortcomings in study design. 
Choosing the appropriate RCT design is pivotal to produce data that can be translated 
into clinical practice.1,2 This review summarizes relevant aspects of design and inter-
pretation of RCTs with the aim of providing the clinician with relevant background 
information when translating current research findings into clinical practice. Moreover, 
it reflects on the principle of equipoise, an ethical concept that is increasingly impor-
tant when large multicentric studies are dominating the impact of medical science on 
clinical practice.
Design of clinical trials
Types and phases of studies
Clinical studies can be separated into nonexperimental or observational and experimental 
or RCTs. Nonexperimental research include case reports, case series, cross-sectional, and 
prospective observational studies, such as case–control and cohort studies. These types 
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of research studies often generate important insights but can-
not provide causal inferential value. RCTs may result in high-
quality data, enabling the description of causal relationships, 
and thus forms the basis of evidence-based medicine.3,4
From the methodological point of view, observational 
studies are investigating both, the exposure and the outcome, 
whereas experimental studies are observing the outcome of 
an assigned exposure. The major advantage of RCTs is the 
straightforward investigation of cause–effect relationships 
with minimal bias and confounding factors.
In RCTs, a predefined study sample is built out of the 
target population (eg, patients with the respective diagnosis) 
and randomly assigned to different groups (eg, standard treat-
ment or placebo vs new treatment). The observed effects of 
investigational treatments at defined time points constitute 
predefined end points.
Clinical trials are commonly classified into phases. Each 
phase is characterized by its design and sample size. Phase I 
trials usually test the interventions in healthy volunteers and 
aim to address safety issues as well as pharmacokinetics and 
dose–response characteristics. Phase II trials are designed 
to determine the evidence of activity or optimal dosage. 
Phase III trials are usually pivotal studies designed to provide 
data for approval by authorities testing new interventions 
either against placebo or against standard treatment for supe-
riority or noninferiority, respectively. Phase IV studies assess 
long-term safety data and are often conducted to receive 
approval for expanded indications after initial approval of the 
intervention. Although there is a considerable variability in 
timing and number of patients enrolled in the different study 
phases, a rule of thumb is that Phase I studies enroll up to 100 
healthy volunteers over a period of up to 2 years, Phase II 
usually up to 300 patients up to 3 years, and Phase III .1,000 
patients for 3–4 years.5,6 For drug development studies, Phase 
III trials are often classified as Phase IIIa (before submission 
for approval authorities) and IIIb (after approval).
Research question and hypothesis
Designing an RCT starts with the development of a clini-
cally relevant research question. Depending on the research 
question, the underlying hypothesis will commonly either 
aim at superiority (comparative trial) or at noninferiority 
(equivalence trial) of one intervention vs another.7,8 The 
intention behind a superiority trial is that Intervention A is 
superior to Intervention B, whereas noninferiority trials are 
designed to prove that the new treatment is at least as good 
as the standard therapy in terms of efficacy but offers other 
advantages such as lower costs, lower toxicity, improved side 
effect profile, or improved forms of administration compared 
to the standard of care. Although straightforward on the first 
approach, the validity of noninferiority trials is sometimes 
jeopardized by the lack of efficacy of the standard treatment 
as well as the appropriate choice of noninferiority margins. 
The noninferiority margin represents a prespecified accept-
able inferiority, which represents the least clinically relevant 
difference among groups, and preserves superiority when 
compared to placebo treatment. The noninferiority margin 
has to be defined a priori and determines the sample size of 
the trials as well as the objective of the trial.
Common study designs
Parallel and crossover designs are the two standard designs 
for RCTs.3,9 Following randomization, subjects will be 
assigned either to receive Intervention A or B (or C, D, E, 
etc) throughout the entire study period (parallel design), or 
subjects are first treated with Intervention A followed by 
Intervention B and vice versa (crossover design). Crossover 
trials can be powerful, since every individual serves as their 
own control, thus variability due to interindividual differ-
ences is excluded.9,10
Whereas randomization is a powerful tool to ensure 
validity in parallel-designed studies, special precautions 
have to be considered in crossover studies to avoid or at least 
account for possible carryover effects. Carryover effects are 
defined as effects that “carry over” from one condition, eg, 
exposure or treatment, to another. Besides randomization 
of the treatment sequence, wash-in and wash-out periods of 
appropriate length are commonly used in crossover studies 
to avoid carryover effects. If more than two interventions are 
compared in a crossover study, the latin square design can be 
used. A latin square design describes a specific (n × n) matrix 
filled with one symbol, each representing one intervention, 
in each row and column, vice versa. Latin square sequences 
are generated to ensure that every intervention is followed 
or preceded just once by any other intervention tested. The 
assumption behind the latin square design is that if there are 
carryover effects, they are better controlled than by simple 
randomization because of the fixed sequence generated.
To test for treatment effects of combined interventions, 
factorial study designs have been proposed where individuals 
are randomly assigned to receive two or more interventions.10,11 
The factorial study design increases the study efficiency 
because it allows for assessment of multiple interventions 
within the same trial. Factorial designs allow for testing the 
effects of each factor on the response variable as well as the 
effects of the interacting factors on the response variable.
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Validity of clinical trials
There have been quality indicators defined for RCTs, and 
these indicators should be considered in both design and 
reporting of RCTs.5,8,12 These quality indicators include 
internal and external validity.
internal validity
High internal validity means that the differences observed 
between groups are related to the intervention tested in the 
trial. This means, for example, that the reduction in mortality 
in the study population is really attributed to the intervention 
and not to other factors, such as age, sex, or comedications. 
The internal validity of a clinical trial is directly related to 
appropriate design, conduction, and reporting of the study. 
The two main threats to internal validity are bias and random 
error. Bias hereby refers to a systematic error that leads to 
a systematic deviation of the results from the truth due to 
flaws in the design, conduction, or reporting of the trial.5,8,13 
Typical sources of bias are flaws in collection, statistical 
analysis, or interpretation of study data. Consequently, the 
true difference between study groups may be either under- or 
overestimated.
The four main sources of bias in clinical trials are selection 
bias, performance bias, detection bias, and attrition bias.14,15 
Selection bias is usually controlled by randomization. The 
main goal of randomized trials is therefore to assure that each 
individual has an equal probability to be assigned to one or 
the other treatment. Randomization also allows to balance 
known and unknown confounders in order to make control 
and treatment groups as balanced as possible. Practically, this 
can be realized by random allocation (eg, by using opaque 
envelopes, allocation tables, or computer-based random 
number generators).8,16 Allocation concealment is another 
key factor for successful randomization, this concept means 
that all people who are involved in the recruitment process 
cannot predict the next group assignment.17,18 Allocation 
concealment prevents specific patients from being assigned to 
one or the other group by the investigator, possibly resulting 
in dysbalance or systematic exaggeration of study results. 
Allocation concealment can be realized by separating the 
person who is generating random allocation and the person 
who is recruiting patients. In addition, performance bias 
occurs if there is insufficient adherence to the study protocol 
either by the participant or the investigator. Although data 
on adherence are important for the interpretation of RCTs, 
they are usually underreported.7
Detection bias refers to systematically different out-
come assessments among study groups. Detection bias may 
occur if the outcome assessment is affected by the group 
membership of the assessed individual. The risk of detection 
bias may increase with close subject or assessor interaction 
or increased margin of discretion by the assessor. For both 
performance and detection bias, the major source is the indi-
vidual perception of the investigator about the advantages or 
disadvantages of the different investigational treatments. The 
most important measure to reduce these sources of bias is the 
blinding of the investigators including the study physician. 
While balancing for possible confounders is easy in large 
RCTs, design of smaller trials should employ techniques 
such as block randomization or a priori stratification to 
reduce the risk of dysbalanced groups due to confounders. 
However, stratification techniques must be defined a priori 
and are associated with special requirements regarding the 
statistical analysis. Typical examples of confounders in RCTs 
are sex, age, and severity of disease. Another way to address 
confounding is to employ multivariable analysis methods to 
adjust for the effects of confounders.1,19 It is worth noting that 
adjusting for confounders needs to be done before random-
ization since postrandomization adjustment for covariates 
jeopardizes the effects of randomization. Performance bias 
is the consequence of systematic intergroup differences in 
the investigational intervention or of exposure factors that 
are not related to the intervention.20 This form of bias can be 
avoided through blinding. Blinding can be single-blind (if 
just the patient or the assessor do not know the group assign-
ment), double-blind (if both, the assessor and the patient do 
not know the group assignment), and triple-blind (if addi-
tionally, the person who performs the statistical analysis is 
not aware of the group assignment). Blinding techniques are 
frequently limited when investigational new medical devices 
or procedures are tested, as these can usually be easily dis-
tinguished from control conditions. In placebo-controlled 
pharmacological trials, effort should be put into producing 
a placebo that is as similar as possible to the study drug. For 
safety reasons, rapid unblinding should be possible in the 
case of adverse events or emergencies.
Attrition bias occurs if there are systematic differences 
in the number of participants dropping out of the study 
among the study groups.3 There are reasons for drop outs 
such as 1) participants may withdraw informed consent, 
2) participants may become uncontactable, and 3) partici-
pants or investigators violate the study protocol or refuse 
to continue treatment for whatever reason. To control for 
attrition bias, most studies are nowadays analyzed according 
to the intention-to-treat (ITT) approach, which means all 
participants that have been randomized will be included in 
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the final analysis, regardless whether they completed the 
study or dropped out.10 In addition to the ITT principle, the 
handling of missing data should also be reported. There are 
different types of missing data. Data missing completely 
at random means that the lost data are independent from 
observable variables and unobservable parameters of interest; 
therefore, the remaining subjects with full data sets are still 
fully randomized from the sample population, and the further 
analysis will not be biased by the missing data. Missing at 
random describes a situation where the missing data are not 
random but cannot be related to a mechanism depending on 
unobserved data. Missing not at random means that data are 
neither missing completely at random nor missing at random, 
for example, when the missing data are related to the reason 
why this data are missing. There are different ways to handle 
missing data in clinical trials such as the last observation 
carried forward method, multiple imputation techniques, or 
mixed methods in case of missing values within repeated 
measures.10
Although bias can be voluntarily reduced by appropriate 
study design and good clinical practice, the chance of random 
error remains due to the intrinsic variability of the measured 
data by pure chance. The most feasible way to improve the 
estimate of random error is to recruit a sufficient number of 
subjects21 according to a sample size calculation or power 
analysis.5 Random error can be divided into two types of 
errors with respect of hypothesis testing. Type I error refers 
to the probability of drawing a false-positive conclusion by 
incorrect rejection of a true null hypothesis, whereas Type II 
error refers to the probability of a false-negative conclusion 
by rejecting a false null hypothesis.5 In a simplified way, 
Type I error describes the phenomenon of detecting a differ-
ence that is not really present, whereas a Type II error leads 
to neglecting an effect that is really present. Given these 
facts, it become obvious that sample size calculation needs 
to be performed a priori.5,13
external validity
External validity describes the extent to which the results 
of an RCT can be generalized into clinical practice and the 
general population.14 This means, for example, if an RCT 
showed that the antihypertensive Drug A is able to reduce 
the mortality in the study sample of hypertonic patients as 
compared to placebo, Drug A can also reduce the mortality 
in all hypertonic patients. It is worth noting that internal 
validity of a study is the prerequisite of its external validity 
since incorrect data due to missing internal validity can, per 
se, not be applied to the general population.8 Even if internal 
validity is assumed, insufficient external validity may reduce 
the clinical relevance of an RCT.17 The study sample of an 
RCT is defined as the patients enrolled in the trial out of 
the population of theoretically accessible patients (target 
population). Practically, the target population represents 
all patients with the disease that should be studied, whereas 
the accessible population includes all patients who could 
be screened. Finally, the study sample is constituted by all 
patients who have been successfully enrolled into the trial. 
By carefully setting inclusion and exclusion criteria, specific 
study samples can be selected, but it also bears the risk of 
jeopardizing generalizability. Van Spall et al19 reviewed the 
eligibility criteria of RCTs published in high-impact general 
medical journals and showed that exclusion criteria are often 
not well reported and that women, children, and elderly 
patients are commonly excluded from RCTs.
Reporting of RCT data
In 1996, the Consolidated Standards of Reporting Trials 
(CONSORT) were introduced to improve the reporting 
of RCT data and enhance the quality of newly designed 
clinical trials.22 The CONSORT statements have been 
revised and updated twice since then to adapt for new 
methodological evidence and for the implementation of 
additional experiences.2,12,13 The CONSORT 2010 statement 
provides a template for the flow diagram of the study process 
(Figure 1) and a 25-item checklist (Table 1) of information 
that should be reported in both groups in parallel random-
ized trials.4,13,23
Additional extensions and modifications have been pub-
lished for cluster-randomized trials,8,24 noninferiority and 
equivalence trials,25–27 nonpharmacological treatments,9,28 
herbal interventions,9,29 and pragmatic trials.11,30 Nowadays, 
the majority of medical journals state in their authors instruc-
tions that reporting of clinical trial data must be in accor-
dance with the CONSORT statements and that illustration 
of the sequence of study procedures must comply with the 
CONSORT flow chart design (Figure 1) to be considered for 
publication. Thus, both the CONSORT statements and the 
CONSORT flow chart have become a widely used standard 
in scientific medical publishing.
To improve transparency of clinical trials, databases such 
as ClinicalTrials.gov have been founded to track changes 
between the planned and the published study and to keep 
researchers updated about ongoing clinical trials. In these 
databases, studies have to be registered before the enrollment 
of the first patient. The majority of medical journals ask 
for the registration in a study database as a prerequisite for 
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publication.11,31 However, there are still numerous clini-
cal trials without complying to these standards published, 
especially since many of the journals, editors, and reviewers 
are not reinforcing the strict compliance with these quality 
assurance measures.
Furthermore, the manuscript should be written in a clear 
and concise way, there should be a strict separation between 
results and interpretation, and authors should not overes-
timate their results, especially in the absence of statistical 
significance. Potential conflict of interest of each author 
should be clearly disclaimed, and funding sources should 
be identified.6,32
interpretation of RCT data
After assessing internal and external validity by checking 
adequate randomization, complete reporting of data and inter-
ventions, blinding if applicable, and selection of meaningful 
end points, one should assess the validity of the primary sta-
tistical analysis. This means first to assess, if an ITT analysis 
was performed and how missing data were handled.
If an efficacy analysis is performed after excluding certain 
subjects, the exclusion criteria should have been defined a priori. 
It is worth noting that an efficacy analysis should be considered 
hypothesis generating, and their results should be confirmed in 
subsequent RCTs. In case of a subgroup analysis, it is necessary 
to assess whether the subgroups have been defined a priori and 
whether they are defined by baseline characteristics to consider 
this analysis valid as confirmatory analysis. If one of these two 
prerequisites is not fulfilled, the subgroup analysis should be 
viewed solely as a hypothesis-generating technique warranting 
further confirmation in a subsequent RCT.
Harhay et al33 reviewed 146 RCTs in the field of intensive 
care that have been published between 2007 and 2013 in 
16 high-impact or critical care journals.8,12 The authors con-
cluded that most RCTs in intensive care have “negative” results 
and are powered according to unrealistic treatment effects, 
particularly if mortality was used as primary end point.
Even if RCTs reporting a statistically significant differ-
ence, estimates of the magnitude of these effects should be 
provided to guide the reader if these differences are clinically 
meaningful. Among the numerous ways how this could be 
performed, absolute risk reduction (ARR) and relative risk 
reduction (RRR) as well as the calculation of the number 
needed to treat (NNT) are commonly used. ARR is calculated 
Figure 1 Flow diagram for parallel randomized trials comparing two groups.
Notes: According to the CONSORT statement, the different phases of a randomized controlled trial can be separated into enrollment, allocation, follow-up, and data 
analysis. These phases should be described exactly with the respective number of patients to provide a quick and simple overview of the study process. Reproduced from 
Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32,13 with permission 
of BioMed Central.
Abbreviation: CONSORT, Consolidated Standards of Reporting Trials.
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by subtracting the risk of one treatment by the risk for the 
other treatment. For example, in the Acute Respiratory Dis-
tress Syndrome Network (ARDSnet) trial comparing lower 
and traditional tidal volumes in ARDS patients,8,34 the risk 
of death before discharge was 31% in the low tidal volume 
group and 39.8% in the group receiving higher tidal volumes. 
Therefore, the ARR was 8.8% favoring low tidal volume 
ventilation. The RRR is calculated as the ratio of the relative 
Table 1 CONSORT 2010 checklist of information to include when reporting a randomized trial
Section/topic Item number Checklist item
Title and abstract 1a Identification as a randomized trial in the title
1b Structured summary of trial design, methods, results, and conclusions
introduction 2a Scientific background and rationale
2b Specific objectives or hypothesis
Methods
Trial design 3a Description of trial design (eg, parallel, factorial) including allocation ratio
3b important changes to methods after trial commencement including reasons (eg, eligibility criteria)
Participants 4a eligibility criteria
4b Settings and locations where the data were collected
interventions 5 Description of interventions with sufficient details to allow repetition (eg, dosage, timing, etc)
Outcomes 6a Definition of prespecified primary and secondary outcome measures including their assessment
6b Any changes to trial outcomes after the trial commenced with reasons
Sample size 7a How sample size was determined
7b explanation of interims analysis or stopping guidelines when applicable
Randomization
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomization, details on restrictions (eg, blocking and block sizes)
Allocation concealment 
mechanism
9 Mechanism used to implement the random allocation sequence (eg, sequentially numbered 
containers), describing any steps taken to conceal the sequence until interventions were assigned
Allocation concealment 
implementation
10 who generated the random allocation sequence, who enrolled participants, and who assigned 
participants to interventions
Blinding 11a if done, who was blinded after assignment to interventions (eg, participants, care providers, 
outcome assessors) and how
11b if relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup or adjusted analyses
Results
Participants flow 13a For each group, the number of participants who were randomly assigned received intended 
treatment and were analyzed for the primary outcome
13b For each group, losses and exclusions after randomization with respective reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b why the trial was ended or stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analyzed 16 For each group, number of participants (denominator) included in each analysis and whether the 
analysis was by original assigned group
Outcomes and 
estimation
17a For each primary and secondary outcome, results for each group, and the estimated effect size 
and its precision (eg, 95% confidence intervals)
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended
Ancillary analysis 18 Results of any other analysis performed, including subgroup and adjusted analyses, distinguishing 
prespecified from explanatory
Harms 19 All important harms or unintended effects in each group
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if applicable, multiplicity 
of analyses
Generalizability 21 Generalizability (external validity, applicability) of the trial findings
22 Interpretation consistent with results, balancing harms and benefits, and considered other 
relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (eg, supply of drugs), role of funders
Notes: Reproduced from Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 
2010;11:32,13 with permission of BioMed Central. it may be instrumental in critically assess manuscripts of randomized controlled trials and support designing a study 
protocol.
Abbreviation: CONSORT, Consolidated Standards of Reporting Trials.
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risk of the treatment group (RR, eg, ratio of both mortality 
rates) divided by 1 (the relative risk of the control group 
is by definition 100%). In the example of the ARDSnet 
study, the RRR can be calculated as (31/39.8) -1=-0.22, 
representing a RRR of 22% for the low tidal volume group 
compared to traditional tidal volumes. The RRR frequently 
leads to overestimation of the treatment effects, so usually 
the ARR should be reported whenever possible.15,35 The 
NNT is derived directly from the ARR and is calculated 
by dividing 1 by the ARR. In the example of the ARDSnet 
trial, the NNT would be 1/0.088=11.4, which means that 
11.4 patients needed to be ventilated with low tidal volumes 
to experience one patient with an additional response, in this 
case survival.
Although RRR, ARR, and NNT can provide informa-
tion about the magnitude of the treatment effect, they are 
strongly related to the variability of the measured parameter 
and the sample size. Therefore, confidence intervals should 
be reported to provide information about the accuracy of the 
findings.16,36 In the ARDSnet study, the 95% confidence inter-
vals for the difference in mortality between groups were 2.4% 
and 15.3%.18,34 This means that with a certainty of 95%, the 
difference in mortality (ARR) between the lower and higher 
tidal volume groups was between 2.4% and 15.3%.
Principle of equipoise
Depending on the predefined clinical research question and 
statistical considerations, RCTs are frequently designed to 
determine superiority, noninferiority, or equivalence of a 
new (experimental) intervention relative to an established 
standard-of-care treatment.7,8 Before randomly assigning 
patients to one or more of the competing study arms, inves-
tigators involved in both design and conduction of clinical 
trials need to be free of any treatment preferences, which 
means there is genuine uncertainty about the best treatment 
regimen for the disease of interest.37,38 This so-called principal 
of equipoise constitutes an ethical prerequisite for conducting 
an RCT. However, clinical investigators commonly face the 
moral dilemma where emerging data (eg, arising from pre-
ceding Phase II trials) provide a strong signal of efficacy for 
an experimental treatment, and the existing standard-of-care 
treatment, although being considered efficacious, is in need 
of improvement due to only minor impacts on an otherwise 
unfavorable course of a disease.
For instance, basilar artery occlusion is a devastating 
disease leading to death in up to 90% of untreated acute 
ischemic stroke patients, and there is still uncertainty about its 
preferred treatment regimen.39 Intravenous thrombolysis with 
tissue plasminogen activator constitutes the only approved 
therapy for acute ischemic stroke that prevents patients from 
permanent disability and death when initiated within 4.5 hours 
from symptom onset.40 Recanalization rates, however, are 
low, particularly in patients suffering from major occlu-
sions, and majority of patients with basilar artery occlusion 
do not clinically benefit from intravenous thrombolysis.39,41 
On the other hand, endovascular treatment of acute ischemic 
stroke results in remarkably higher recanalization rates than 
intravenous thrombolysis, and recently published RCTs 
have shown strong treatment effects on clinical outcomes 
in patients treated interventionally for anterior circulation 
stroke (ie, excluding basilar arty occlusion).42 The current 
body of scientific knowledge on treatment of basilar artery 
occlusion (ie, mostly based on meta-analyses of observational 
studies and registries), however, does not favor one treatment 
regimen over the other – while intravenous thrombolysis can 
be initiated in any acute stroke-ready hospital in a timely 
manner (which is crucial for favorable outcomes), higher 
recanalization rates achieved with endovascular therapy 
may be counterbalanced by procedural delays, resulting in 
longer times to reperfusion.43–45 Consequently, current lack 
of scientific evidence for acute treatment of basilar artery 
occlusion justifies null hypothesis testing in this context 
and meets ethical requirements for clinical equipoise, and 
meanwhile, a large RCT has been initiated to properly address 
this question.46,47 Nevertheless, from a clinician investigator’s 
standpoint and with knowledge of the aforementioned RCT 
results on endovascular treatment for anterior circulation 
stroke, personal equipoise may become compromised when 
withholding endovascular therapy for basilar artery occlusion 
and will lead to significant moral objections. Once there is 
no longer clinical or personal equipoise, continuation of and 
contribution to an RCT should be reconsidered, otherwise 
serious biases may be introduced (eg, selection bias – less 
severely affected stroke patients with basilar artery occlusion 
are more likely cleared for randomization than more severely 
affected patients).38
Preplanned interims analyses at certain time points 
or recruited sample sizes during an ongoing RCT aid in 
maintaining clinical equipoise.48 Trial data are analyzed 
for benefit, harm, or futility, and decisions on continuation 
or termination of the trial will be made by an independent 
data safety monitoring board according to clinical equipoise 
(eg, large effect size suggests superiority of one treatment 
over the other and clinical equipoise no longer exists), among 
others. However, it is worth noting that when repeated signifi-
cance testing on accumulating data is performed, adjustment 
of the hypothesis testing procedure is necessary to maintain 
the overall significance level.
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Limitations
Although a systematic review of the literature was performed, 
this article is influenced by personal opinion and the indi-
vidual experience of the authors. Owing to the diversity of 
clinical research, this article offers an overview over com-
monly used clinical research scenarios but may not cover 
every aspect of clinical trial design.
Summary of recommendations
In RCTs, the research question should be scientifically rel-
evant and clearly stated. Randomization and stratification 
techniques should be employed as well as the use of placebo 
control or blinding whenever possible to reduce the risk of 
bias. Clinically relevant end points should be defined a priori, 
and an unbiased analysis and report of the study results should 
be warranted. Both significant and nonsignificant results 
should be objectively reported and published. Structured 
study design and performance as indicated in the CONSORT 
statement should be employed, as well as the registration of 
the RCT in a public trial database. Besides careful conduc-
tion and interpretation of the study, potential conflict of 
interests and funding sources should be disclaimed. Finally, 
the principle of equipoise should be met prior to and during 
the conduction of an RCT.
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